Erenumab (Alimovig®) |
CGRP receptor |
Migraines |
SC |
70 or 140 mg/ml |
PFS, SureClick AI |
Sarilumab (Kevzara®)
|
IL-6 receptor
|
Rheumatoid arthritis
|
SC
|
150 mg/1.14 ml,
200 mg/1.14 ml
|
PFS, pre-filled pen
|
Emicizumab (Hemlibra®) |
Factor IXa / X |
Haemophilia A |
SC |
30 mg/ml,
150 mg/ml |
Injection, IV solution vial |
Denosumab (Prolia®)
|
RANK-L
|
Postmenopausal osteoporosis
|
SC
|
Prolia: 60 mg/ml
Xgeva: 70 mg/ml
|
PFS or vial
|
Adalimumab (Humira®) |
TNF-α |
Rheumatoid arthritis |
SC |
40-80 mg/0.8
ml |
PFS, pre-filled pen or vial |
Trastuzumab (Herceptin®)
|
HER2
|
Breast cancer
|
IV/SC
|
IV: 150 mg/single-dose vial, 400 mg/ multi-dose vial
SC: (120mg/2000units)/ml
|
IV: lyophilized powder
SC: single-dose vial
|
Rituximab (Mabthera) |
CD20 |
Non-Hodgkin’s lymphoma |
IV/SC |
IV:10
mg/ml (10 and 50 ml vials) |
Single-dose vial |
Teprotumumab (Tepezza®) |
|
Thyroid eye disease |
IV |
500
mg/single-dose vial |
Lyophilized powder |
Belimumab (Benlysta®)
|
BLyS
|
Systemic lupus erythematosus
|
IV/SC
|
IV: 120 or 400 mg/vial
SC: 200 mg/ml
|
IV: lyophilized powder
SC: PFS or AI
|
Palivizumab (Synagis®) |
RSV |
Respiratory syncytial virus |
IM |
100
mg/ml |
Powder for reconstitution (injection) |
Muromonab (OKT3) (discontinued) |
CD3 |
Transplantation rejection |
IVP |
1 mg/ml |
Injectable solution |
Gemtuzumab (Mylotarg®) (discontinued) |
CD33 |
Acute myeloid
leukaemia (AML) |
IV |
4.5 mg/ml |
Single-dose vial |